A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer (NCT06007937)
A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers
🩺 Plain-English Summary (8th-Grade Level)
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
Age range: 19 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering West Harrison (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Rockville Centre, New York
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.